Inspire Pharmaceuticals, Inc. Announces Appointment of Joe Schachle as Vice President, Marketing and Sales

Apr 10, 2001, 01:00 ET from Inspire Pharmaceuticals, Inc.

    DURHAM, N.C., April 10 /PRNewswire Interactive News Release/ --
 Inspire Pharmaceuticals, Inc. (Nasdaq:   ISPH) is pleased to announce the
 appointment of Joe Schachle as Vice President, Marketing and Sales.
     In this position, Mr. Schachle will be responsible for strategic product
 planning as well as the development of a marketing and sales infrastructure in
 North America to handle Inspire's future commercial efforts in various
 therapeutic areas.  With more than 12 years of experience in the
 pharmaceutical industry, and over a half dozen successful product launches, he
 brings to Inspire the skills and expertise required to build the foundation
 for bringing products to market.
     Mr. Schachle most recently served as Director of Marketing at
 GlaxoSmithKline in the respiratory area, with overall responsibility for the
 launch of Advair for asthma in the US.  Over his nine-year tenure at
 GlaxoSmithKline, Mr. Schachle held various positions in sales, marketing and
 new product planning.  These responsibilities included brand management of the
 CNS products Imitrex, Amerge and Wellbutrin SR and the HIV products Epivir,
 Retrovir and Mepron.  Prior to joining GlaxoSmithKline he was with The Upjohn
 Company (now Pharmacia).  Mr. Schachle holds a BBA in Marketing from James
 Madison University and an MBA from Old Dominion University.
     "We are very pleased to have Joe Schachle join Inspire's senior management
 team at such a crucial time in our evolution," said Greg Mossinghoff, Senior
 Vice President and Chief Business Officer, Inspire.  "He brings with him a
 wealth of experience in the creation and management of sales and marketing
 strategies, and a strong background in product launches.  We know he will play
 a critical role in helping Inspire shape its future direction as it moves its
 products through the clinic towards commercialization."
 
     Inspire Pharmaceuticals, Inc. discovers and develops new drugs to treat
 diseases characterized by deficiencies in the body's innate defense mechanisms
 of mucosal hydration and mucociliary clearance, as well as other non-mucosal
 disorders.  Mucosal defense mechanisms are the natural way that the body
 defends its mucosal surfaces against dust, pollutants, bacteria and viruses.
 Inspire's lead product candidates target respiratory and ophthalmic diseases
 with inadequate current treatments and which represent large therapeutic
 market opportunities.  Inspire has four product candidates in clinical
 development, and has entered into development and commercialization alliances
 with Genentech, Inc., Kissei Pharmaceutical Co., Ltd., Santen Pharmaceutical
 Co., Ltd. and Kirin Brewery Co., Ltd.  Inspire's products are based on
 proprietary technology relating to P2Y receptors. Inspire is exploring other
 target diseases where it believes P2Y receptors play important biological
 roles.
 
     The forward-looking statements in this news release relating to
 management's expectations and beliefs are based on preliminary information and
 management assumptions.  Such forward-looking statements are subject to a wide
 range of risks and uncertainties that could cause results to differ in
 material respects, including those relating to product development, revenue
 and earnings expectations, intellectual property rights and litigation,
 competitive products, results of clinical trials, the need for additional
 research and testing, delays in manufacturing, funding, and the timing and
 content of decisions made by regulatory authorities, including the U.S. Food
 and Drug Administration.  Further information regarding factors that could
 affect the Company's results is included in the Company's filings with the
 Securities and Exchange Commission.  The Company undertakes no obligation to
 publicly release the results of any revisions to these forward-looking
 statements that may be made to reflect events or circumstances after the date
 hereof to reflect the occurrence of unanticipated events.
 
     CONTACT:  Lauren Bowen, Manager, Human Resources of Inspire
 Pharmaceuticals, Inc., 919-941-9777; or Emily Poe of Noonan/Russo,
 212-696-4455, for Inspire Pharmaceuticals, Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X46172374
 
 

SOURCE Inspire Pharmaceuticals, Inc.
    DURHAM, N.C., April 10 /PRNewswire Interactive News Release/ --
 Inspire Pharmaceuticals, Inc. (Nasdaq:   ISPH) is pleased to announce the
 appointment of Joe Schachle as Vice President, Marketing and Sales.
     In this position, Mr. Schachle will be responsible for strategic product
 planning as well as the development of a marketing and sales infrastructure in
 North America to handle Inspire's future commercial efforts in various
 therapeutic areas.  With more than 12 years of experience in the
 pharmaceutical industry, and over a half dozen successful product launches, he
 brings to Inspire the skills and expertise required to build the foundation
 for bringing products to market.
     Mr. Schachle most recently served as Director of Marketing at
 GlaxoSmithKline in the respiratory area, with overall responsibility for the
 launch of Advair for asthma in the US.  Over his nine-year tenure at
 GlaxoSmithKline, Mr. Schachle held various positions in sales, marketing and
 new product planning.  These responsibilities included brand management of the
 CNS products Imitrex, Amerge and Wellbutrin SR and the HIV products Epivir,
 Retrovir and Mepron.  Prior to joining GlaxoSmithKline he was with The Upjohn
 Company (now Pharmacia).  Mr. Schachle holds a BBA in Marketing from James
 Madison University and an MBA from Old Dominion University.
     "We are very pleased to have Joe Schachle join Inspire's senior management
 team at such a crucial time in our evolution," said Greg Mossinghoff, Senior
 Vice President and Chief Business Officer, Inspire.  "He brings with him a
 wealth of experience in the creation and management of sales and marketing
 strategies, and a strong background in product launches.  We know he will play
 a critical role in helping Inspire shape its future direction as it moves its
 products through the clinic towards commercialization."
 
     Inspire Pharmaceuticals, Inc. discovers and develops new drugs to treat
 diseases characterized by deficiencies in the body's innate defense mechanisms
 of mucosal hydration and mucociliary clearance, as well as other non-mucosal
 disorders.  Mucosal defense mechanisms are the natural way that the body
 defends its mucosal surfaces against dust, pollutants, bacteria and viruses.
 Inspire's lead product candidates target respiratory and ophthalmic diseases
 with inadequate current treatments and which represent large therapeutic
 market opportunities.  Inspire has four product candidates in clinical
 development, and has entered into development and commercialization alliances
 with Genentech, Inc., Kissei Pharmaceutical Co., Ltd., Santen Pharmaceutical
 Co., Ltd. and Kirin Brewery Co., Ltd.  Inspire's products are based on
 proprietary technology relating to P2Y receptors. Inspire is exploring other
 target diseases where it believes P2Y receptors play important biological
 roles.
 
     The forward-looking statements in this news release relating to
 management's expectations and beliefs are based on preliminary information and
 management assumptions.  Such forward-looking statements are subject to a wide
 range of risks and uncertainties that could cause results to differ in
 material respects, including those relating to product development, revenue
 and earnings expectations, intellectual property rights and litigation,
 competitive products, results of clinical trials, the need for additional
 research and testing, delays in manufacturing, funding, and the timing and
 content of decisions made by regulatory authorities, including the U.S. Food
 and Drug Administration.  Further information regarding factors that could
 affect the Company's results is included in the Company's filings with the
 Securities and Exchange Commission.  The Company undertakes no obligation to
 publicly release the results of any revisions to these forward-looking
 statements that may be made to reflect events or circumstances after the date
 hereof to reflect the occurrence of unanticipated events.
 
     CONTACT:  Lauren Bowen, Manager, Human Resources of Inspire
 Pharmaceuticals, Inc., 919-941-9777; or Emily Poe of Noonan/Russo,
 212-696-4455, for Inspire Pharmaceuticals, Inc.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X46172374
 
 SOURCE  Inspire Pharmaceuticals, Inc.